Edwards Lifesciences (EW) Stock Could Be 11% Undervalued on Its TAVR and EVOQUE Story - simplywall.st
π Edwards Lifesciences (EW) trades at $86.28 with a calculated fair value of $96.92, implying an 11% undervaluation.
π° The company reported full-year revenue of $6,303.5 million and net income of $1,075.6 million.
π An early TAVR indication is expected to receive approval in the second quarter, driving future growth.
π¬ The transcatheter tricuspid valve EVOQUE is scheduled for launch in 2024 as a first-in-class therapy.
βοΈ Current P/E ratio of 46.2x is significantly higher than the industry average of 24.5x and peer average of 25.1x.
β οΈ Tariffs could negatively impact profit margins if they weigh heavily on operations.
π₯ Competition may limit expected growth rates in the TAVR procedure market.
Bullish Signals
- The stock is modeled as undervalued by 11% with a fair value target of $96.92 versus the current price of $86.28.
- Upcoming approval for an early TAVR indication in Q2 represents a significant multi-year growth opportunity.
- Global policy and guideline changes are expected to enhance revenue streams for the company's cardiovascular portfolio.
- The 2024 launch of the EVOQUE tricuspid valve will make Edwards the first company to offer this specific therapy, aiding market share gains.
- Recent shareholder returns have been positive, with a 15.32% total return over the past year.
Risk Factors
- The current P/E ratio of 46.2x is well above the US Medical Equipment industry average of 24.5x and peer average of 25.1x.
- High valuation multiples suggest the market may already be pricing in future growth, leaving less room for error if expectations are challenged.
- Tariffs could weigh heavily on margins, potentially pressuring profitability.
- Competition could limit the expected growth in TAVR procedures.
Full Analysis
Edwards Lifesciences (EW) is currently trading at $86.28, with full-year revenue of $6.3 billion and net income of $1.07 billion. The article argues the stock is undervalued by 11%, suggesting a fair value of $96.92 based on growth assumptions tied to its cardiovascular portfolio. However, valuation metrics present a mixed picture, as the current P/E ratio of 46.2x significantly exceeds the US Medical Equipment industry average of 24.5x and peer average of 25.1x.
The primary bullish drivers include the anticipated approval of an early TAVR indication in the second quarter and policy changes that could expand revenue streams globally. Additionally, the planned 2024 launch of the transcatheter tricuspid valve EVOQUE is expected to position Edwards as a market leader, potentially increasing its share in this new therapy area.
Despite the upside potential, risks remain regarding tariffs impacting margins and competition limiting growth in TAVR procedures. The article concludes that while the fair value model suggests undervaluation, investors must weigh these concerns against the high current multiple to determine if expectations are sustainable.